AbbVie Inc (ABBV)vsKailera Therapeutics, Inc. Common Stock (KLRA)
ABBV
AbbVie Inc
$227.23
+6.25%
HEALTHCARE · Cap: $391.50B
KLRA
Kailera Therapeutics, Inc. Common Stock
$22.88
-2.55%
HEALTHCARE · Cap: $2.45B
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
KLRA
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$227.23
$81.01 premium
Intrinsic value data unavailable for KLRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
No standout strengths identified
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : KLRA
KLRA has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : KLRA
The primary concerns for KLRA are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 22/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Kailera Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Kailera Therapeutics, Inc. is a biotechnology company focused on developing innovative gene therapies for rare genetic diseases, leveraging advanced technologies to address unmet medical needs. The company's proprietary platform is designed to enhance the precision and effectiveness of therapeutic interventions, targeting various genetic disorders. By collaborating with leading research institutions and leveraging a robust intellectual property portfolio, Kailera aims to bring transformative treatments to patients and position itself as a leader in the gene therapy market. As it advances its product pipeline, Kailera is committed to delivering sustainable value to its investors and stakeholders.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?